Development PipelineTisotumab vedotin

an investigational antibody–drug conjugate directed to tissue factor

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

innovaTV 301: Recurrent or metastatic cervical cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

innovaTV 205: Recurrent or metastatic cervical cancer (monotherapy and in combination with other agents)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

innovaTV 207: Advanced solid tumors

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of tisotumab vedotin and ongoing clinical trials

Detailed information about tisotumab vedotin clinical trials

Related Videos

Tisotumab Vedotin Proposed Mechanism of Action